Samsung Medical Center
Samsung Medical Center
Republic of Korea, Seoul
Keon Hee Yoo
23 years of experience
Clinic is certified :
Acute lymphoblastic leukemia treatment cost in the Republic of Korea runs between $55,000 and $118,000 for major interventions. Comprehensive diagnostics including an extended analysis of blood range from $100 to $200. Total expenses depend on the leukemia subtype, treatment phase, and hospital tier. Patients can see 30-50% savings compared to the US. Most specialized care is concentrated in Seoul.
Typical Acute Lymphoblastic Leukemia Treatment Costs in Republic of Korea
Bookimed Expert Insight: High-risk patients needing complex interventions should consider Asan Medical Center. It handles massive volumes, treating over 2,700 patients simultaneously with high success rates. For those prioritizing safety through technology, SNUBH is best. As Korea's first digital hospital, its BESTcare system significantly reduces medical errors. Samsung Medical Center is the top choice for multidisciplinary oncology care. It has been recognized among the World's Best Hospitals for three consecutive years.
| Republic of Korea | Turkey | Austria | |
| Chemotherapy for breast cancer | from $19,200 | from $1,200 | from $15,000 |
| Bone marrow transplantation | from $55,000 | from $36,000 | from $140,000 |
| Autologous bone marrow transplantation | from $42,000 | from $31,500 | from $50,000 |
| Allogenic bone marrow transplantation from an unrelated donor | from $145,000 | from $80,000 | from $180,000 |
| Allogenic bone marrow transplantation from a related donor | from $75,000 | from $65,000 | from $150,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Acute lymphoblastic leukemia treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Acute lymphoblastic leukemia treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Acute lymphoblastic leukemia treatment journey.
The doctor is the Head of the Oncology Department, specializing in chemotherapy for lung cancer, head and neck cancer, and esophageal cancer. The focus is on utilizing new clinical drugs to improve treatment outcomes. With extensive experience in oncological therapies, the doctor is at the forefront of cancer treatment advancements.
The doctor is a pediatrician and hematologist specializing in the treatment of leukemia and aplastic anemia. They are skilled in performing bone marrow transplants for children. The doctor completed their studies at Seoul National University and gained experience as an Assistant Professor in the Department of Pediatrics at Samsung Medical Center. They furthered their expertise as a Research Fellow at Indiana University. Since 2011, they have been contributing to the pediatrics department at Samsung Medical Center.
The doctor is an expert in oncoplastic surgery and breast cancer, with extensive experience from prestigious institutions. The doctor holds an M.D. degree from Seoul National University College of Medicine and an M.S. degree in Surgery from the same institution. Additionally, the doctor earned a B.S. in biological sciences from the Korea Advanced Institute of Science and Technology (KAIST) and a Ph.D. in Surgery from Seoul National University Graduate School.
South Korea offers comprehensive acute lymphoblastic leukemia care at Joint Commission International-accredited tertiary centers. Treatment includes multi-phase chemotherapy, minimal residual disease monitoring, and hematopoietic stem cell transplantation. Specialized facilities provide advanced immunotherapies like CAR-T cell therapy and targeted agents for Philadelphia chromosome-positive cases.
Bookimed Expert Insight: South Korea is home to the first digital hospital in the country, Seoul National University Bundang Hospital. This digitalization ensures rapid data processing and treatment initiation. Major centers like Asan Medical Center perform over 65,000 operations yearly. High patient volumes allow these hospitals to maintain specialized teams for complex infection control during induction chemotherapy.
Patient Consensus: Patients note that treatment intensity is high. They emphasize the importance of choosing large university hospitals to ensure access to superior infection management and blood transfusion support.
Patients in South Korea undergo risk stratification using molecular subtyping and minimal residual disease (MRD) monitoring. Doctors categorize cases by age, genetic mutations, and early treatment response. JCI-accredited facilities like Severance Hospital then tailor chemo-intensity and bone marrow transplant protocols to individual genetic profiles.
Bookimed Expert Insight: Clinical data from Seoul National University Hospital shows that digitalization drives South Korea's high success rates. Their fully digital systems prevent errors by tracking real-time lab adjustments. Clinics like Asan Medical Center perform over 65,000 operations annually, allowing teams to refine risk-stratified pathways through immense patient volumes.
Patient Consensus: Patients note that risk is re-checked throughout treatment rather than decided once. They emphasize that genetic results often change their category and influence transplant decisions.
Seoul's major tertiary centers are globally recognized for acute lymphoblastic leukemia (ALL) care. Asan Medical Center, Samsung Medical Center, and Seoul National University Hospital lead in outcomes. These JCI-accredited facilities provide advanced bone marrow transplants and intensive chemotherapy for complex hematologic cases.
Bookimed Expert Insight: Patient volume is a primary indicator of leukemia expertise in South Korea. Hospitals like Samsung Medical Center serve over 2,000,000 patients annually. This massive scale allows hematology teams to manage rare ALL subtypes effectively. Large centers also provide critical 24-hour ICU support mandatory for intensive induction therapy.
Patient Consensus: Patients emphasize that for ALL, choosing a hospital with high-volume transplant capacity is essential. Many travelers prioritize Seoul-based centers because they offer rapid molecular testing and specialized infection-management protocols.
South Korean oncology centers balance pediatric acute lymphoblastic leukemia (ALL) cures with quality of life. They use risk-adapted strategies to achieve 92% survival rates. Doctors adjust treatment intensity using minimal residual disease monitoring. This tailored approach minimizes toxicities like cardiotoxicity and cognitive impairment in standard-risk children.
Bookimed Expert Insight: Quality of life is prioritized through massive institutional scale and digital precision. Severance Hospital treats 4,000,000 patients annually and holds JCI accreditation for safety. Large centers like Asan Medical Center perform over 65,000 surgeries yearly. This high volume allows Korean specialists to refine protocols that reduce long-term side effects while maintaining top-tier outcomes.
Patient Consensus: Parents note that treatment is highly structured with family involvement in safety decisions. Families often weigh avoiding late effects against relapse risk to protect a child's future learning ability.
International patients can access novel leukemia therapies in South Korea through major university hospitals. South Korea ranks among the top 10 global trial locations. Over 200 certified centers provide streamlined 30-day trial approvals. Most international participation occurs during phase II or III global clinical studies.
Bookimed Expert Insight: While South Korea excels in research, trial eligibility for non-residents is often stricter than standard treatment. Asan Medical Center serves over 180,000 patients annually and handles 45% of Korea's heart transplants. This massive clinical volume allows their teams to manage complex Acute Lymphoblastic Leukemia cases that other regions might decline.
Patient Consensus: Patients note that language barriers and intensive paperwork are often bigger hurdles than the medical treatment itself. They recommend preparing full English records, specifically genetic results and prior therapy history, before requesting a trial evaluation.